1.
Determinants and measures of quality in oral anticoagulation therapy
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2007-09-29, Vol.25 (1), p.61-66
2.
Preclinical and clinical data for factor Xa and “Universal” reversal agents
by Milling, Truman J., MD
The American journal of emergency medicine, 2016, Vol.34 (11), p.39-45
3.
Reversal of target-specific oral anticoagulants
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2013-05-09, Vol.36 (2), p.195-202
4.
Preclinical and clinical data for factor Xa and "universal" reversal agents
by Milling, Jr, Truman J
The American journal of emergency medicine, 2016-11, Vol.34 (11S), p.39-45
5.
Impact on patient care: patient case through the continuum of care
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2009-11-10, Vol.29 (2), p.167-170
6.
What you should know about the 2008 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th) on Antithrombotic and Thrombolytic Therapy
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2009-11-17, Vol.29 (2), p.219-226
7.
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE
by Khorana, Alok A., MD
Clinical therapeutics, 2017, Vol.39 (7), p.1396-1408
8.
Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (fro...
by Spyropoulos, Alex C., MD
The American journal of cardiology, 2008, Vol.102 (7), p.883-889
9.
Update in bridging anticoagulation
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2011-02-15, Vol.31 (3), p.259-264
10.
The changing characteristics of atrial fibrillation patients treated with warfarin
by Putnam, Andrew
Journal of thrombosis and thrombolysis, 2015-07-01, Vol.40 (4), p.488-493
11.
Top practice-changing articles over the last two years
by Kaatz, Scott
Journal of thrombosis and thrombolysis, 2013-03-03, Vol.35 (3), p.325-332
12.
Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)
by Barnes, Geoffrey D
Journal of thrombosis and thrombolysis, 2013-05-08, Vol.37 (2), p.171-176
13.
Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)
by Barnes, Geoffrey D
Journal of thrombosis and thrombolysis, 2012-07-14, Vol.35 (1), p.10-14
14.
The Cost‐Effectiveness of Different Management Strategies for Patients on Chronic Warfarin Therapy
by Lafata, Jennifer Elston
Journal of general internal medicine, 2000-01, Vol.15 (1), p.31-37
15.
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
by Heneghan, Carl, Dr
The Lancet (British edition), 2012, Vol.379 (9813), p.322-334
16.
CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge
by Laliberté, François
Current medical research and opinion, 2018-11-02, Vol.34 (11), p.1967-1974
17.
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation
by Kaatz, Scott
Current medical research and opinion, 2018-02-01, Vol.34 (2), p.275-284
18.
Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis
by Lafata, J E
Journal of thrombosis and thrombolysis, 2000-06, Vol.9 Suppl 1 (1), p.S13-S19
19.
Congestive Heart failure and QRS duration: Establishing prognosis study
by SHENKMAN, Heather J
Chest, 2002, Vol.122 (2), p.528-534
20.
Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
by Laliberté, François
Current medical research and opinion, 2014-08, Vol.30 (8), p.1513-1520
